Voice-controlled CRISPR / Cas 9 enhanced sonodynamic therapy for hepatocellular carcinoma is a novel strategy using acoustic control of CRISPR / Cas 9 gene editing system to enhance the killing effect of hepatocellular liver cancer (sonodynamic therapy, HCC) by knocking out antioxidant gene NFE2L2 in tumor cells. Acodyndynamic therapy is a non-invasive therapy that uses the combination of ultrasound and drugs to produce harmful reactive oxygen species (reactive oxygen species, ROS) at the tumor site to kill tumor cells. CRISPR / Cas 9 is a technique that enables precise gene editing and can be used to knockout or repair specific genes. Voice-controlled CRISPR / Cas 9 enhanced sonotherapy for hepatocellular carcinoma can use ultrasound stimulation to realize the release and transfection of CRISPR / Cas 9 system at the tumor site, thus reducing the antioxidant capacity of tumor cells and enhancing the effect of sonodynamic therapy.